{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:08:05Z","timestamp":1779448085584,"version":"3.53.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"BIAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00415-026-13752-x","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T05:55:30Z","timestamp":1777096530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-reported outcomes and experiences with COMT inhibitors in the management of motor fluctuations in Parkinson\u2019s disease: a UK-based nested cross-sectional study"],"prefix":"10.1007","volume":"273","author":[{"given":"Alastair J.","family":"Noyce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Akindele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma-Louise","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olina","family":"Efthymiadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Peri\u00f1an","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4201-5886","authenticated-orcid":false,"given":"Glynn","family":"Harrison-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"13752_CR1","unstructured":"National Institute for Health and Care Excellence. (2017). Parkinson\u2019s disease in adults (NICE Guideline No. NG71). https:\/\/www.nice.org.uk\/guidance\/ng71."},{"key":"13752_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/mds.30162","volume":"40","author":"RMA de Bie","year":"2025","unstructured":"de Bie RMA, Katzenschlager R, Swinnen B, Peball M, Lim SY, Mestre TA, Perez Lloret S, Coelho M, Aquino C, Tan AH, Bruno V, Dijk JM, Heim B, Lin CH, Kauppila LA, Litvan I, Spijker R, Seppi K, Costa J, Sampaio C, Fox SH, Silverdale MA (2025) Update on treatments for Parkinson\u2019s disease motor fluctuations - an International Parkinson and Movement Disorder Society evidence-based medicine review. Mov Disord 40:776\u2013794","journal-title":"Mov Disord"},{"key":"13752_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","volume":"97","author":"T Pringsheim","year":"2021","unstructured":"Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, de Bie RMA, Roze E, Miyasaki JM, Hauser RA, Espay AJ, Martello JP, Gurwell JA, Billinghurst L, Sullivan K, Fitts MS, Cothros N, Hall DA, Rafferty M, Hagerbrant L, Hastings T, O\u2019Brien MD, Silsbee H, Gronseth G, Lang AE, Guideline Subcommittee of the AAN (2021) Dopaminergic therapy for motor symptoms in early Parkinson Disease practice guideline summary: a report of the AAN guideline subcommittee. Neurology 97:942\u2013957","journal-title":"Neurology"},{"key":"13752_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.parkreldis.2013.04.022","volume":"19","author":"M van der Eijk","year":"2013","unstructured":"van der Eijk M, Nijhuis FAP, Faber MJ, Bloem BR (2013) Moving from physician-centered care towards patient-centered care for Parkinson\u2019s disease patients. Parkinsonism Relat Disord 19:923\u2013927","journal-title":"Parkinsonism Relat Disord"},{"key":"13752_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/hex.12497","volume":"20","author":"N Zizzo","year":"2017","unstructured":"Zizzo N, Bell E, Lafontaine AL, Racine E (2017) Examining chronic care patient preferences for involvement in health-care decision making: the case of Parkinson\u2019s disease patients in a patient-centred clinic. Health Expect 20:655\u2013664","journal-title":"Health Expect"},{"key":"13752_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.pec.2013.10.031","volume":"94","author":"N Joseph-Williams","year":"2014","unstructured":"Joseph-Williams N, Elwyn G, Edwards A (2014) Knowledge is not power for patients: a systematic review and thematic synthesis of patient-reported barriers and facilitators to shared decision making. Patient Educ Couns 94:291\u2013309","journal-title":"Patient Educ Couns"},{"key":"13752_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/jep.13507","volume":"27","author":"M Moleman","year":"2021","unstructured":"Moleman M, Regeer BJ, Schuitmaker-Warnaar TJ (2021) Shared decision-making and the nuances of clinical work: concepts, barriers and opportunities for a dynamic model. J Eval Clin Pract 27:926\u2013934","journal-title":"J Eval Clin Pract"},{"key":"13752_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0324999","volume":"20","author":"K Orayj","year":"2025","unstructured":"Orayj K (2025) Trends in Parkinson\u2019s disease medication prescribing patterns in the UK: an interrupted time series analysis (2019\u20132024). PLoS ONE 20:e0324999","journal-title":"PLoS ONE"},{"key":"13752_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mds.27882","volume":"35","author":"HJ Kim","year":"2020","unstructured":"Kim HJ, Mason S, Foltynie T, Winder-Rhodes S, Barker RA, Williams-Gray CH (2020) Motor complications in Parkinson\u2019s disease: 13-year follow-up of the CamPaIGN cohort. Mov Disord 35:185\u2013190","journal-title":"Mov Disord"},{"key":"13752_CR10","unstructured":"South East London Area Prescribing Committee Formulary recommendation. Available at https:\/\/www.selondonics.org\/wp-content\/uploads\/dlm_uploads\/RE9B521.pdf Last accessed January 2026."},{"key":"13752_CR11","unstructured":"Airedale, Wharfedale and Craven CCG. Formulary Chapter 4. Available at https:\/\/www.airedale-trustformulary.nhs.uk\/chaptersSubDetails.asp?FormularySectionID=4&SubSectionRef=04.09.01&SubSectionID=E100. Last accessed January 2026."},{"key":"13752_CR12","unstructured":"Bedfordshire and Luton Joint Formulary. Available at https:\/\/www.bedsformulary.nhs.uk\/chaptersSubDetails.asp?FormularySectionID=4&SubSectionRef=04.09.01&SubSectionID=A100&drugmatch=4884. Last accessed January 2026."},{"key":"13752_CR13","unstructured":"AccessPD registry. https:\/\/umed.io\/access-cohort-studies\/accesspd\/."},{"key":"13752_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00651-z","volume":"10","author":"YH Chang","year":"2024","unstructured":"Chang YH, Peri\u00f1an MT, Wilson M, Noyce AJ (2024) AccessPD as a next generation registry to accelerate Parkinson\u2019s disease research. NPJ Parkinsons Dis 10:66","journal-title":"NPJ Parkinsons Dis"},{"key":"13752_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997) The Parkinson\u2019s Disease Questionnaire (PDQ-39): development and validation of a Parkinson\u2019s disease summary index score. Age Ageing 26:353\u2013357","journal-title":"Age Ageing"},{"key":"13752_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000455863","volume":"48","author":"K Horvath","year":"2017","unstructured":"Horvath K, Aschermann Z, Kovacs M, Makkos A, Harmat M, Janszky J, Komoly S, Karadi K, Kovacs N (2017) Changes in quality of life in Parkinson\u2019s Disease: How large must they be to be relevant? Neuroepidemiology 48:1\u20138","journal-title":"Neuroepidemiology"},{"key":"13752_CR17","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s40120-025-00765-3","volume":"14","author":"J Jimenez-Shahed","year":"2025","unstructured":"Jimenez-Shahed J, Malaty IA, Azulay JP, Parab A, Yan CH, Kandukuri PL, Kukreja P, Zamudio J, Gillespie A, Antonini A (2025) Clinical, humanistic, and economic value of \u201cGood ON-Time\u201d in advanced Parkinson\u2019s Disease: a multinational real-world study. Neurol Ther 14:1475\u20131493","journal-title":"Neurol Ther"},{"key":"13752_CR18","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","volume":"51","author":"UK Rinne","year":"1998","unstructured":"Rinne UK, Larsen JP, Siden A, Worm-Petersen J (1998) Entacapone enhances the response to Levodopa in parkinsonian patients with motor fluctuations. Neurology 51:1309\u20131314 (Nomecomt Study Group)","journal-title":"Neurology"},{"key":"13752_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","volume":"105","author":"WH Poewe","year":"2002","unstructured":"Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, Celomen Study G (2002) Efficacy and safety of Entacapone in Parkinson\u2019s Disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105:245\u2013255","journal-title":"Acta Neurol Scand"},{"key":"13752_CR20","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","volume":"74","author":"DJ Brooks","year":"2003","unstructured":"Brooks DJ, Sagar H (2003) Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson\u2019s Disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 74:1071\u20131079","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13752_CR21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, Bi-Park i (2016) Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15:154\u2013165","journal-title":"Lancet Neurol"},{"key":"13752_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","volume":"74","author":"AJ Lees","year":"2017","unstructured":"Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P (2017) Opicapone as adjunct to Levodopa therapy in patients with Parkinson\u2019s Disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74:197\u2013206 (Investigators B-S)","journal-title":"JAMA Neurol"},{"key":"13752_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.707723","volume":"12","author":"Z Song","year":"2021","unstructured":"Song Z, Zhang J, Xue T, Yang Y, Wu D, Chen Z, You W, Wang Z (2021) Different Catechol-O-Methyl Transferase inhibitors in Parkinson\u2019s Disease: a Bayesian network meta-analysis. Front Neurol 12:707723","journal-title":"Front Neurol"},{"key":"13752_CR24","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.2147\/NDT.S279362","volume":"18","author":"WH Jost","year":"2022","unstructured":"Jost WH (2022) Evaluating Opicapone as add-on treatment to Levodopa\/DDCI in patients with Parkinson\u2019s Disease. Neuropsychiatr Dis Treat 18:1603\u20131618","journal-title":"Neuropsychiatr Dis Treat"},{"key":"13752_CR25","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/ene.13624","volume":"25","author":"A Antonini","year":"2018","unstructured":"Antonini A, Tinazzi M, Abbruzzese G, Berardelli A, Chaudhuri KR, Defazio G, Ferreira J, Martinez-Martin P, Trenkwalder C, Rascol O (2018) Pain in Parkinson\u2019s Disease: facts and uncertainties. Eur J Neurol 25:917-e969","journal-title":"Eur J Neurol"},{"key":"13752_CR26","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.3233\/JPD-202126","volume":"10","author":"AD van Halteren","year":"2020","unstructured":"van Halteren AD, Munneke M, Smit E, Thomas S, Bloem BR, Darweesh SKL, Bloem BR, Brundin P (2020) Personalized care management for persons with Parkinson\u2019s Disease. J Parkinsons Dis 10:S11\u2013S20","journal-title":"J Parkinsons Dis"},{"key":"13752_CR27","unstructured":"Ongentys 50 mg hard capsules. Summary of Product Characteristics. BIAL Pharmaceuticals 2024. ."},{"key":"13752_CR28","unstructured":"Comtess 200 mg film-coated Tablets. Summary of Product Characteristics. Orion Pharma 2022."},{"key":"13752_CR29","unstructured":"Kent Surry Sussex Academic Health Science Network. One size doesn\u2019t fit all: reimagining medicines information for patients (2023). Available at https:\/\/healthinnovation-kss.com\/wp-content\/uploads\/2023\/03\/State-of-the-Nation-Report-FINAL.pdf."},{"key":"13752_CR30","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/mds.20602","volume":"20","author":"KA Grosset","year":"2005","unstructured":"Grosset KA, Bone I, Grosset DG (2005) Suboptimal medication adherence in Parkinson\u2019s disease. Mov Disord 20:1502\u20131507","journal-title":"Mov Disord"},{"key":"13752_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2024.108189","volume":"239","author":"W Wu","year":"2024","unstructured":"Wu W, Lu X, Zhang L, Hong D (2024) Effectiveness and safety of different catechol-O-methyl transferase inhibitors for patients with Parkinson\u2019s disease: Systematic review and network meta-analysis. Clin Neurol Neurosurg 239:108189","journal-title":"Clin Neurol Neurosurg"},{"key":"13752_CR32","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1111\/ene.15990","volume":"30","author":"G Harrison-Jones","year":"2023","unstructured":"Harrison-Jones G, Marston XL, Morgante F, Chaudhuri KR, Castilla-Fern\u00e1ndez G, Di Foggia V (2023) Opicapone versus Entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson\u2019s disease new to catechol-O-methyltransferase (COMT) inhibitor treatment. Eur J Neurol 30:3132\u20133141","journal-title":"Eur J Neurol"},{"key":"13752_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/padi\/8408907","volume":"2025","author":"G Harrison-Jones","year":"2025","unstructured":"Harrison-Jones G, Green W, Bainbridge J (2025) The cost-effectiveness of Opicapone versus Entacapone as adjuvant therapy for Levodopa-treated individuals with Parkinson\u2019s disease experiencing end-of-dose motor fluctuations. Parkinsons Dis 2025:8408907","journal-title":"Parkinsons Dis"},{"key":"13752_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2217\/nmt-2021-0057","volume":"12","author":"C Schofield","year":"2022","unstructured":"Schofield C, Chaudhuri KR, Carroll C, Sharma JC, Pavese N, Evans J, Foltynie T, Reichmann H, Zurowska L, Soares-da-Silva P, Lees A (2022) Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson\u2019s disease. Neurodegener Dis Manag 12:77\u201391","journal-title":"Neurodegener Dis Manag"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13752-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13752-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13752-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:43:57Z","timestamp":1779446637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13752-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["13752"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13752-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AJN is an associate editor for The Journal of Parkinson\u2019s Disease and reports consultancy and personal fees from: AbbVie, Alchemab, AstraZeneca, Bial, Britannia, Sosei Heptares and Umedeor, grants from: Aligning Science Across Parkinson\u2019s (ASAP), Alchemab, Barts Charity, Cure Parkinson\u2019s, Innovate UK, Michael J Fox Foundation, National Institute for Health and Care Research, The Medical College of Saint Bartholomew\u2019s Hospital Trust, and Parkinson\u2019s UK. ES, OE, and TPT have nothing to report. LA, RM, GHJ and MI are employees of BIAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"287"}}